Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEUTRALIZE: SZC for Hyperkalemia and Metabolic Acidosis in CKD
NCT04727528Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Primary completion
- Sep 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 3 trial of sodium zirconium cyclosilicate in hyperkalemia, metabolic acidosis, sponsored by AstraZeneca. Started Mar 2021; status: terminated.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemiametabolic acidosis
Beyond the preview
Go deeper on NCT04727528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04727528.